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1. Introduction 
Bioprospecting is the exploration of biological material for commercially valuable genetic 
and biochemical properties (Reid et al., 1993). This chapter will focus on the search for 
activities that could form the basis of new pharmaceuticals. Historically, most of the active 
ingredients in medicines have been natural products (Sneader, 1996), and natural products 
continue to form a productive source of new drugs (Newman and Cragg, 2007; Butler, 2008). 
Given that most drug discovery activity takes place in companies in the developed world 
and that most biodiversity is found in countries of the southern hemisphere, there needs to 
be a means whereby access to biodiversity is possible under terms and conditions that are 
mutually acceptable. After hundreds of years of unregulated collection of samples for many 
different purposes, the United Nations produced a framework for preserving the world’s 
biodiversity while encouraging the sustainable use of biodiversity. This Convention on 
Biological Diversity has been widely accepted, and it is discussed in the following section. 
The chapter will continue with descriptions of various attempts to calculate an economic 
value for biodiversity, followed by an outline of current bioprospecting practices. 
2. United Nations Convention on Biological Diversity 
The United Nations Convention on Biological Diversity (CBD) (www.biodiv.org) was one of 
the major outcomes of the Earth Summit in Rio de Janeiro in June 1992. The CBD has three 
main goals:  
 the conservation of biodiversity 
 the sustainable use of the components of biodiversity 
 the sharing of benefits arising from the commercial and other utilization of genetic 
resources in a fair and equitable way 
Signatories to the CBD recognise that countries have sovereign rights over their genetic and 
biological resources (i.e., biodiversity) within their boundaries, and agree to the conditions 
in the CBD for the preservation and sustainable use of biodiversity.  
In relation to accessing natural products for drug discovery, the CBD has a number of 
Articles (see Appendix) that set the tone for future interactions between companies and 
research organisations with countries with desired biodiversity. Biodiverse-rich countries 
that have ratified the CBD have to facilitate access to their biological resources (Article 15.2). 
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Such access must be in accordance with appropriate legislation (Article 15.1), and be on 
mutually agreed terms (Article 15.4) involving prior informed consent (Article 15.5).  The 
source country is expected to be involved in collaborative research and development 
projects relating to its biodiversity (Article 15.6) and the source country should benefit from 
technology transfer (Article 16.2), from the results of research (Article 15.7) and from sharing 
of commercial benefits resulting from use of its biodiversity (Article 15.7). Article 8(j) also 
commits signatories to preserving the traditional knowledge of indigenous and local 
communities and to promoting their involvement in developing wider applications of their 
knowledge; however, there is little guidance on how this might be achieved. 
Since 1992, 192 countries and the European Union have signed or ratified the CBD, the notable 
exception being the USA. However, issues relating to access to biological resources have not 
been fully resolved. Only about 25 countries have introduced new regulations to facilitate 
access, and the vast majority of countries still have to formulate the appropriate laws. 
To assist the implementation of bioprospecting under the CBD, the Conference of the Parties 
(the official CBD body) adopted the Bonn Guidelines on ‘Access to Genetic Resources and 
Fair and Equitable Sharing of the Benefits Arising out of their Utilization’ (Secretariat, 2002). 
These are not legally binding, but they are intended to help all parties follow best practices 
in setting up bioprospecting agreements. Various professional bodies have responded to the 
Bonn Guidelines with their own recommendations. For example, the International 
Federation of Pharmaceutical Manufacturers and Associations has published its views on 
‘industry best practices’ and the enabling steps that governments need to take with regard 
to regulating bioprospecting (IFPMA, 2007). The Biotechnology Industry Organisation of the 
USA has produced detailed guidelines for its members about engaging in bioprospecting 
(BIO-1, n.d.). These cover the general conduct of bioprospecting, sharing of financial benefits 
and of results of research, intellectual property rights, and conservation and sustainable use 
of biodiversity. The organisation has also published a model Material Transfer Agreement 
for use in bioprospecting operations (BIO-2, n.d.). There is a very useful resource published 
by the International Institute for Sustainable Development as an ‘access and benefit-sharing 
management tool’ and an accompanying handbook (IISD, 2007). This provides a step-by-
step guide to obtaining prior informed consent, reaching mutually agreed terms, agreeing 
benefit-sharing arrangements, and dealing with issues relating to traditional knowledge and 
conservation. 
The Bonn Guidelines are likely to be superseded by the Nagoya Protocol on Access to 
Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their 
Utilization to the Convention on Biological Diversity (Secretariat, 2011). This is a new treaty 
under the CBD that was adopted in Nagoya in October 2010. It will be operational once 50 
countries ratify it (40 have done so by the end of July 2011). The aim of the Protocol is to 
provide greater legal certainty about all aspects of bioprospecting. In particular, it is 
intended to establish more predictable conditions for access to biodiversity and to ensure 
appropriate benefit-sharing. The Protocol deals more explicitly than previous documents 
with the use of traditional knowledge associated with genetic resources: contracting parties 
have to ensure that local communities have provided prior informed consent and that there 
is fair and equitable benefit-sharing with the relevant communities. The Nagoya Protocol 
also recognises that genetic resources are rarely confined to a single country and that 
traditional knowledge related to use of genetic resources is often shared by different 
communities. The Protocol demands involvement and cooperation of the relevant parties. 
A major weakness in the implementation of the CBD with respect to bioprospecting has 
been the slow development of national systems for governing access to biodiversity. The 
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Nagoya Protocol is explicit about the responsibilities of signatories to create ‘national focal 
points’ and ‘competent national authorities’ to make available information on how to access 
genetic resources and traditional knowledge and to be responsible for granting access to 
biodiversity. In Africa, a diverse range of policies and laws relevant to access and benefit-
sharing is in place in some countries, but these are most developed in South Africa through 
the National Environmental Management: Biodiversity Act (10 of 2004) (‘the Biodiversity 
Act’)  and the regulations passed under this Act in 2008.  The Biodiversity Act requires 
bioprospectors to obtain a permit from the Government for bioprospecting involving 
indigenous biological resources, and for the export of these resources. Prior informed 
consent is required with landowners and indigenous communities before a permit is issued. 
Benefit-sharing agreements must be entered into with indigenous communities who use the 
resource traditionally, or who have knowledge of its properties (Wynberg et al., 2009).  
3. Value of bioresources 
A key issue in bioprospecting is benefit-sharing. However, much of the debate on this topic 
assumes that there are benefits to share. The historical successes in drug discovery based on 
natural products would suggest that there should be a continued appetite for accessing 
natural products for use in drug discovery programmes. Despite this, the pharmaceutical 
industry, in general, has reduced its use of natural products (Harvey, 2008), and there are 
few current examples of large-scale programmes designed to access a wide variety of 
natural products collected from their native environment. Moreover, advances in techniques 
for manipulating microbes to produce novels chemicals make the use of locally sourced 
bacterial samples more attractive to industry (Kingston, 2011). Never-the-less, it is 
reasonable to ask what an appropriate price might be for biodiversity, its conservation and 
its availability for bioprospecting. This is an area with much debate but little consensus (see, 
for example, Castree, 2003). 
Future royalty streams from blockbuster drugs (drugs that generate $1 billion in sales per year) 
directly or indirectly derived from bioresources were anticipated to contribute significantly to 
the conservation of biodiversity in source countries, and to the development of indigenous 
knowledge holder communities. However the age of blockbuster drugs seems to largely be 
over, and the pharmaceutical sector, as it is currently structured, is unable to deliver enough 
new products to market to generate revenues sufficient to sustain its own growth. Nearly all 
major drug developers are critically examining current R&D practices and, in some cases, 
considering a radical overhaul of their R&D models (Kaitlin, 2010). Only 13 natural product–
derived drugs were approved in the United States between 2005 and 2007 (Harvey, 2008), and 
FDA approvals of new drugs reached a 24-year low in 2007 (Li & Vederas, 2009). With the 
contraction and consolidation seen in the pharmaceutical industry, and with only 3 in 10 new 
products generating revenues equal to or greater than average pharmaceutical industry R&D 
costs (Kaitlin, 2010), it would seem that royalty streams from natural product-derived 
pharmaceuticals are too uncertain to be included in the valuation of biodiversity.  
A pragmatic approach to valuation is to focus on the monetary value paid by end users. In the 
early 1990s, Merck & Co. entered an agreement with the National Biodiversity Institute of 
Costa Rica, INBio, that provided a defined amount of cash (reported as $1 million) for a certain 
number of samples; although this deal is frequently mentioned in articles on the pros and cons 
of bioprospecting, key elements of the financial terms are still confidential, notably the 
payment per sample. More recently, GlaxoSmith Kline had an arrangement with the 
biotechnology company Extracta in Brazil: at its reported value of $3.2 million for a collection 
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of 30,000 samples (Dias & da Costa, 2007), this does not seem like a high price - about $100 per 
sample.  The Swiss company Novartis also had an agreement with a Brazilian organisation, 
Bioamazonia, reported to be $4 million for 10,000 samples of micro-organisms. It should be 
noted that political concerns in Brazil about inappropriate commercialisation of its biodiversity 
caused both interactions to be terminated, highlighting the need for clear national focal points 
and competent authorities, as called for in the Nagoya Protocol. 
In a development from academic collaborations on natural products and drug discovery, the 
Strathclyde Institute for Drug Research, UK acted as a broker for natural product samples 
provided by its collaborators and offered samples under licence to companies for bioassay. 
Because each species could be used several times, the cumulative return on a single extract 
could be quite impressive, reaching $500-1,500 per gram. This can be compared with 
commodity prices obtained for a known herbal medicine that has proved active in double-
blind clinical trials: raw material costs for Hypericum perforatum (St John’s wort) are $8-10 per 
kg. However, there is currently little demand from companies for samples of natural 
product extracts, and the brokerage activity has stopped. 
Another approach to valuation of biodiversity has argued that a value can be put on the 
potential contribution of an area of land to drug discovery (Simpson et al., 1996; Rausser & 
Small, 2000). Depending on the assumptions used, this varied from $21 per hectare 
(Simpson et al., 1996) to $9,177 per hectare (Rausser & Small, 2000). The latter valuation was 
thought to be sufficient to provide an economic reward to sustain biodiversity conservation.  
A later paper (Costello & Ward, 2003) sought to explain the very different valuations 
reached by the previous authors. They concluded that Rausser and Small’s focus on species 
in biodiversity hotspots was largely responsible. 
Another approach to valuation of biodiversity used the pharmaceutical industry figures for 
costs and rewards of drug discovery and development to formulate a discounted cash flow 
model that gave a Net Present Value for an extract in a screening programme (Artuso, 1997). 
This was $487 per extract. A similar approach was used to explore the impact of varying the 
balance between upfront payments for sample supply and long-term royalties from sales of 
commercialised products (Lesser & Krattinger, 2007). In theory, more value is attached to a 
deal with an emphasis on royalty payments, but the authors note that larger up-front fees 
may be more of an incentive for conservation of biodiversity. The same approach was used 
to explore the potential added value of traditional knowledge and of pre-screened extracts. 
On average, use of samples suggested by traditional knowledge was expected to double the 
value of the deal. However, it is unlikely that this approach, which is based on averaging the 
theoretical outcome of testing large collections of samples, is appropriate for use of samples 
from traditional medicinal uses. These are more likely to be commercialised (if at all) on an 
individual basis. In addition to the possibility of providing a source for new chemical 
entities or derivatives, traditional medicinal plants may be commercialised as standardised 
plant extracts developed into polymolecular botanical medicines, dietary supplements or 
functional foods. The value of a registered botanical medicine may be considerable. In 
December 2005, the German Federal Institute for Drugs and Medical Devices (BfArM, Bonn) 
approved a new licence for the use of a proprietary extract of the root of the South African 
plant Pelargonium sidoides, (EPs® 7630), known as Umckaloabo, as a drug (Conrad et al., 
2007). This registered liquid herbal medicine has been reported to have an annual turnover 
in Germany alone in 2006 of €80,000,000 (Brendler & van Wyk, 2008). 
In-country fractionation and screening could also, potentially, raise the value of a collection 
of natural product extracts on the basis of reducing the risk of failure to the commercial 
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development partner. However, there has to be the necessary infrastructure and expertise to 
allow the screening, and the preliminary tests have to be relevant to the commercial partner 
(Lesser & Krattinger, 2007).  
The discussion above has only considered direct monetary benefits. However, both the Bonn 
Guidelines and the Nagoya Protocol list possible non-monetary benefits in addition to the 
monetary ones (Table 1). The non-monetary benefits need to be looked at seriously because 
technology transfer and improvements in capacity may contribute to sustainable development 
in biodiversity-rich countries, although that assumption has been questioned (Castree, 2003). 
 
1. Monetary benefits may include, but not be limited to: 
a. Access fees/fee per sample collected or otherwise acquired; 
b. Up-front payments; 
c. Milestone payments; 
d. Payment of royalties; 
e. Licence fees in case of commercialization; 
f. Special fees to be paid to trust funds supporting conservation and sustainable use of biodiversity; 
g. Salaries and preferential terms where mutually agreed; 
h. Research funding; 
i. Joint ventures; 
j. Joint ownership of relevant intellectual property rights. 
2. Non-monetary benefits may include, but not be limited to: 
a. Sharing of research and development results; 
b. Collaboration, cooperation and contribution in scientific research and development programmes, 
particularly biotechnological research activities, where possible in the Party providing genetic 
resources; 
c. Participation in product development; 
d. Collaboration, cooperation and contribution in education and training; 
e. Admittance to ex situ facilities of genetic resources and to databases; 
f. Transfer to the provider of the genetic resources of knowledge and technology under fair and 
most favourable terms, including on concessional and preferential terms where agreed, in 
particular, knowledge and technology that make use of genetic resources, including 
biotechnology, or that are relevant to the conservation and sustainable utilization of biological 
diversity; 
g. Strengthening capacities for technology transfer; 
h. Institutional capacity-building; 
i. Human and material resources to strengthen the capacities for the administration and 
enforcement of access regulations; 
j. Training related to genetic resources with the full participation of countries providing genetic 
resources, and where possible, in such countries; 
k. Access to scientific information relevant to conservation and sustainable use of biological 
diversity, including biological inventories and taxonomic studies; 
l. Contributions to the local economy; 
m. Research directed towards priority needs, such as health and food security, taking into account 
domestic uses of genetic resources in the Party providing genetic resources; 
n. Institutional and professional relationships that can arise from an access and benefit-sharing 
agreement and subsequent collaborative activities; 
o. Food and livelihood security benefits; 
p. Social recognition; 
q. Joint ownership of relevant intellectual property rights. 
Table 1. Monetary and non-monetary benefits to be considered in bioprospecting 
agreements (from the Nagoya Protocol) 
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Under the CBD, there is a clear need to reach agreement with the source of biodiversity on 
appropriate sharing of benefits arising from any commercialisation. There is also a 
commitment in the CBD to recognise and protect indigenous knowledge about uses of 
biodiversity. When it comes to benefit-sharing from commercial developments from such 
traditional knowledge, agreements can be hard to reach (see Boyd, 1996; Mays & Mazan, 
1996). In part, this can be because of a cultural clash, e.g. where traditional knowledge is 
regarded as communal and not capable of being owned in a Western sense (see Cotton, 
1997; Prathapan & Rajan, 2011). There can certainly be arguments over inventorship when 
the natural products in question are in widespread use, and there are frequent disputes 
about what constitutes appropriate benefits. In some cultures, monetary returns may have 
little meaning, and various attempts have been made to set up, for example, charitable 
foundations to distribute benefits in other ways (Mulholland & Wilman, 2003).  
Various access and benefit-sharing agreements have been analysed (Castree, 2003; 
Mulholland & Wilman, 2003; Medaglia, 2004; Laird & Wynberg, 2008). Clear criteria for 
success, in either economic or conservation terms, are missing so that it is difficult to reach 
objective conclusions. It seems to be extremely unlikely that bioprospecting will be a 
sufficient economic driver to support conservation of biodiversity. Indeed, the case of 
paclitaxel has been cited to show that a bioprospecting success can lead to negative 
consequences (Frisvold & Day-Rubenstein, 2008). Bioprospecting should perhaps be 
examined as an activity with some opportunities for local benefits and one that has to be 
regulated to make sure that it does not endanger biodiversity or deny fair and equitable 
benefits to indigenous knowledge-holders. 
4. Historical successes in pharmaceutical bioprospecting 
Bioprospecting (in terms of seeking leads for new drugs from natural products) can follow 
two main approaches: use of leads from traditional medical uses (i.e., from 
“ethnopharmacology”), and use of natural products as a highly diverse set of chemicals for 
random screening.  
4.1 Traditional medicines 
Historically, nature was the origin of all medicines (Sneader, 1996), and ethnopharmacology 
has provided some very notable past successes, including morphine (isolated in 1804), 
quinine (isolated in 1820), digitoxin (isolated in 1841), ephedrine (isolated in 1897), and 
tubocurarine (isolated in 1935). These compounds, or their analogues and derivatives, are 
still in widespread use. A further 50 examples are given by Cox (1994). More recent 
developments with an association with traditional uses include artemisinin and derivatives 
for malaria and prostratin as an anti-viral (see, e.g., Kingston, 2011).  
The development of a pharmaceutical product (as an appetite suppressant) from the 
traditionally used South African plants in the Hoodia genus was stopped, although the plant 
moved into development as a food supplement (Laird & Wynberg, 2008; van Heerden, 
2008). Unfortunately, the early promise was not upheld and the commercial development 
rights have reverted to CSIR in South Africa. The approach to the commercial development 
of Hoodia was a case with inappropriate agreements between the South African research 
organisation CSIR and commercial development partners: the original agreements did not 
include the holders of the traditional knowledge, the San people. The absence of any 
www.intechopen.com
 
Bioprospecting: Creating a Value for Biodiversity 
 
329 
benefits accruing to the San was subsequently successfully challenged by the South African 
San Council, and a mutually acceptable agreement was finally reached between the CSIR 
and the South African San Council after 18 months of negotiations (Wynberg et al., 2009). 
The more recent efforts to develop a medicinal or dietary supplement product from another 
plant (Sceletium tortuosum) originally used by the San may be instructive: the company 
involved, HG&H Pharmaceuticals (Pty) Ltd,  successfully concluded a prior informed 
consent benefit-sharing agreement with the South African San Council and was also 
awarded the first bioprospecting and export permit to be issued by the South African 
Government (see http://www.zembrin.com/). 
There have also been leads from traditional medicines used as the starting point for the 
development of analogues that become the active ingredients of the final medicinal product. 
An example is podophyllotoxin, a compound isolated from Podophyllum peltatum, a plant 
used traditionally in North America for treating warts: this stimulated the work that led to 
the anti-cancer agent etoposide. Other examples can be found in the review by Newman and 
Cragg (2007), and more details and examples of ethnopharmacological investigations can be 
found in the books by Chadwick and Marsh (1994) and Cotton (1997). As discussed in the 
preceding section, accessing natural products used as traditional medicines can lead to 
many challenges - relating to ownership of intellectual property and benefit-sharing. It is 
also not necessarily a successful strategy for developing pharmaceutical products, as 
evidenced by the failure to date of either Shaman Pharmaceuticals or Phytopharm to 
commercialise new drugs or botanical medicines from traditional medicines. 
4.2 Lucky finds 
Random screening of natural products does not presuppose the existence of particular 
biological activities in any set of natural products: it relies on the assay to detect the activity. 
The key to success is likely to be having the most chemically diverse collection of natural 
products, and this can be approached by using collections from diverse genetic sources. 
Notable successes include the development of cyclosporine A from a fungus (Tolypocladium 
inflatum) collected in Norway, and the development of rapamycin from a microbe 
(Streptomyces hygroscopicus) from Easter Island. The anti-cancer agent paclitaxel was 
discovered as a result of the National Cancer Institute’s large-scale screening of plant 
extracts (Frisvold & Day-Rubenstein, 2008). 
Conservationists have highlighted the fact that 70% of the world’s plant species and more than 
60% of the world’s vertebrate species are found on 1.4% of the land area of the world, and that 
some of the regions containing the greatest biodiversity are being threatened by development 
(Mittermeir et al., 1999). The richest regions have been defined as 25 mega diverse “hotspots” 
on the basis of the number of species found there and the high proportion of endemic species, 
i.e. those that occur naturally only in that region. The hotspots are shown in Table 2 along with 
the number of plant species they contain. Collections from areas with high endemism would 
be expected to yield many unusual compounds. However, apart from INBio’s efforts in Costa 
Rica, there have been no systematic and widespread collections of samples from the 
biodiversity hotspots for bioprospecting. 
Seventy percent of the earth’s surface is covered by sea, and the marine environment 
contains examples of most types of organisms.  There may be more than 10 million species 
of marine macro fauna (Poore and Wilson, 1993) and many more species of marine micro-
organisms. There are few marine-based collections for bioprospecting: possibly, those of 
www.intechopen.com
 
Research in Biodiversity – Models and Applications 
 
330 
Magellan BioScience (www.magellanbioscience.com) in USA and MarBank in Norway. 
There has been relatively little work on bioprospecting such marine biodiversity, although 
salinosporamide from a marine bacteria is in early-stage clinical trials and ecteinascidin 743 
(trabectedin) from a marine tunicate has been approved in Europe for the treatment of some 
cancers.  
 
Hotspot Plant species Endemic species 
Tropical Andes 45,000 20,000 
Penisular Malaysia and Western Indonesia 25,000 15,000 
Mediterranean basin 25,000 13,000 
Mesoamerica 24,000 5,000 
Atlantic Forest, Brazil 20,000 6,000 
Indo-Burma 13,500 7,000 
Madagascar and Indian Ocean Islands 12,000 9,700 
Caribbean 12,000 7,000 
Mountains of south-central China 12,000 3,500 
Brazilian cerrado 10,000 4,400 
Wallacea (Indonesia) 10,000 1,500 
Choco-Darien-Western Ecuador 9,000 2,250 
Guinean forest, West Africa 9,000 2,250 
Cape floristic province, South Africa 8,200 5,700 
Philippines 7,620 5,800 
Polynesia/Micronesia 6,500 3,300 
Caucasus 6,300 1,600 
South-west Australia 5,500 4,300 
Succulent Karoo, South Africa 4,800 1,860 
Western Ghats and Sri Lanka 4,780 2,180 
Californian floristic province 4,400 2,125 
Eastern arc mountains, Tanzania and Kenya 4,000 1,400 
Central Chile 3,400 1,600 
New Caledonia 3,320 2,500 
New Zealand 2,300 1,865 
Table 2. The megadiverse hotspots and their vascular plants. Adapted from the information 
given by Mittermeier et al. (1999). 
New and unusual biodiversity is still being discovered as unusual habitats are being sampled 
(Harvey 2007). Since this biodiversity has never been available for biological testing, it can be 
predicted that novel chemicals with potential as drug leads will be discovered if such 
biodiversity can be accessed for screening. However, this is largely driven by small-scale 
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academic endeavours. Few companies are currently involved in providing access to 
biodiversity samples. Table 3 lists companies cited in 2001 as being active in this area (Harvey, 
2002). Apart from Albany Molecular Research (AMRI), all have gone out of business or 
changed strategy. Analyticon still provides screening samples, but these are prepared as 
synthetic modifications of natural product scaffolds rather than purified natural products. 
 
Company Type of natural 
product
Description Current status 
Drug Discovery 
Ltd, UK 
Plant extracts Worldwide sources
87% of plant families 
6,500 species
Not active
MicroBotanica, 
USA 
Plant extracts Peruvian Amazon
12,000 samples
Not active
BioProspect, 
Australia 
Plant extracts Western Australian
3,000 samples 
Untested species
Focusing on product 
development 
Molecular 
Nature, UK 
Plant 
compounds 
Unusual compounds 
from relatively common 
plants
Not active
AnalytiCon 
Discovery, 
Germany 
Compounds Made to order libraries Synthetic modifications of 
natural product scaffolds 
bioLeads, 
Germany 
Microbial 
extracts 
45,000 actinomycetes 
and other 
microorganisms
Taken over by BioFrontera; 
now a dermatological 
company
InterLink 
Biotechnologies, 
USA 
Microbial 
samples 
33,000 samples Assets sold; no longer 
active in bioprospecting 
Albany Molecular 
Research, USA 
Microbial 
extracts 
Ex-PanLabs collection of 
25,000 microbial species 
Now AMRI; expanded to 
300,000 samples including 
marine and plant species 
Exalpha, USA Microalgae 
compounds
Prefractionated Now lab test company 
Phytera Marine and 
plant extracts 
Neptune library and 
ExPAND tissue culture-
derived samples
Taken over; no longer 
active in bioprospecting 
Diversa, USA Microbial gene 
products 
Small molecules from 
unique gene expression 
pathways 
Now Verenium 
Corporation; changed to 
product development 
based on enzymes 
Cubist, USA Microbial 
extracts 
54,000 partially 
characterised extracts of 
fungi and actinomycetes
Focus on clinical 
development of antibiotics 
Table 3. Companies previously active (in 2001) in providing access to biodiversity for drug 
discovery purposes and their current status. 
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5. Current practices in bioprospecting 
Most bioprospecting is currently performed on a small scale by numerous academic groups 
throughout the world. There are some larger programmes based on multi-group 
collaborations. These include the various International Cooperative Biodiversity Groups 
(ICBG) funded by the NIH in the USA and efforts coordinated by individual universities 
such as Rutgers in New Jersey and Strathclyde in Scotland. ICBG programmes involve US 
institutions and commercial companies with overseas participants in Costa Rica, Fiji, 
Indonesia, Madagascar, Panama, Papua New Guinea, the Philippines, and Vietnam and 
Laos (Cao & Kingston, 2009; Kingston, 2011). Rutgers University hosts a relatively new 
initiative: the Global Institute for BioExploration, GIBEX. This is an international network 
that aims to promote successful drug discovery from biodiversity through developing 
pharmacological screening methods that can be readily transferred to groups in partner 
countries (see http://www.gibex.org/). The University of Strathclyde has a long history of 
research in phytochemistry in collaboration with research groups in institutes overseas. This 
formed the basis for the creation of a worldwide network for drug discovery based on 
natural products. A highly diverse collection of plant extracts was assembled (covering 
more than 90% of the world’s plant families) and used in drug discovery screening assays, 
either with a commercial partner or through collaborations between members of the 
network (see http://www.sidr.org/). 
Very few large pharmaceutical companies have maintained a strong presence in natural 
product-based drug discovery. Novartis has developed extensive collaborations with a few 
academic centres in the Far East, notably in China and Thailand. AstraZeneca had a long 
connection with a group based at Griffith University in Queensland. This continues within 
the Eskitis Institute (see http://www.griffith.edu.au/science-aviation/eskitis-institute-cell-
molecular-therapies). There are smaller specialist companies involved in bioprospecting. 
These include MerLion Pharmaceuticals in Singapore (http://www.merlionpharma.com/) 
and Sequoia Sciences in St Louis, Missouri (http://www.sequoiasciences.com/).   
A different approach has been developed to make use of the structural diversity of isolated 
natural products: in silico drug discovery or virtual screening. In this, the chemical structures 
and physico-chemical properties of compounds are gathered in a computerised database that 
can be searched to find matches either to complement the three-dimensional structure of a 
drug target or the chemical features of a compound with the desired activity. This has been 
used at the University of Strathclyde in its Drug Discovery Portal (www.ddp.strath.ac.uk). 
Chemists can submit structures to the Portal’s database and biologists can propose therapeutic 
targets. Compounds are screened in silico by computational chemists within the Portal against 
the targets and the relevant chemists and biologists are notified of any predicted hits.  The 
chemists then supply compounds to the biologists for testing on real assays against the target.  
Because chemists can only enter compounds into the Portal’s database if they can guarantee 
that they can supply the compounds and because biologists can only suggest targets if they 
have relevant assays available, the reduction to practice can be very rapid after the initial in 
silico screening.  The unique chemical database is rapidly expanding (currently over 14,500 
compounds), with academic scientists from 21 institutions in five continents contributing, and 
the compounds have been shown to be highly diverse but still generally drug-like in their 
properties (Clark et al., 2010; Harvey et al., 2010; Schuster & Wolber, 2010). Another approach 
to using natural products and virtual screening has been developed at the University of 
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Innsbruck, Austria.  Several databases of natural products have been created: a large general 
natural product database (“NPD”) including over 110,000 compounds of molecular weights 
between 150 and 700, a small database of about 10,000 constituents from medicinal plants 
mentioned by Dioscorides (“DIOS” database) and a TCM database of about 10,000 compounds 
known from plants used in Traditional Chinese Medicine (Rollinger et al., 2004; 2009). The 
assumed advantage of using compounds from known medicinal plants is that they may be 
less likely to be toxic than randomly sampled constituents. 
6. Future prospects 
Bioprospecting has been proposed as a potential means to encourage the conservation and 
sustainable use of biodiversity. The legal framework under the auspices of the United 
Nations is slowly being implemented by biodiversity-rich countries, but much still needs to 
be done if there is to be a genuine facilitation of bioprospecting. Perhaps the implementation 
of the Nagoya Protocol will provide the necessary impetus.  
However, the appetite for bioprospecting by pharmaceutical development companies has 
clearly diminished since the Rio Earth Summit in 1992, partly because of the complexities 
relating to access and benefit-sharing, often in the absence of adequate national regulatory 
clarity and institutional capacity. Despite the continuing appearance of successful drug 
development projects based on natural products, there is a sentiment that this approach may 
be too old-fashioned to be considered seriously: screening of natural products for new leads. 
Various technical problems undoubtedly exist with the screening and isolation of natural 
products, but the rewards for overcoming them would seem to justify the effort required, 
and technical solutions are being described in the literature. For example, purification and 
identification of natural products are believed to be difficult and slow: high throughput 
separation methods coupled with sensitive analytical techniques can resolve this (Bugni et 
al, 2008; Hu et al, 2008). Natural products are chemically complex: comparisons of the 
chemical properties of collections of natural products show that they more closely match the 
“chemical space” of successful drugs than collections of synthetic chemicals (Grabowski and 
Schneider 2007; Ganesan 2008). Natural products are reputed to give too many false 
positives on modern screening assays, but phenotypic assays are becoming more and more 
popular and it has been suggested that natural products, with their drug-like properties, are 
well-matched to such cell-based approaches, and extracts of natural products can be 
processed to remove reactive compounds or even convert them into novel drug-like 
structures (Rishton 2008). Natural products may only be available in small amounts: 
techniques for direct synthesis (Sunazuka et al, 2008) or production by molecular biology 
(Kennedy 2008) have been rapidly developing. 
While there is certainly no single “best” way to conduct drug discovery, just as there is not a 
single panacea for all ailments, it is surely time for a fresh look at the relatively unexplored 
opportunities provided by modern approaches to applying natural products in drug 
discovery. Perhaps the lead will have to be provided by the numerous academic groups 
active in bioprospecting. However, these groups would stand more chance of success if they 
could pool resources and work towards finding validated lead compounds that are likely to 
be suitable for development into medicines for unmet therapeutic needs. The growth of 
translational research and the establishment of centres of translational research will enable 
academic groups to become essential partners in pharmaceutical innovation. 
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7. Appendix 
7.1 Articles 15 and 16 from the United Nations Convention on biological diversity 
Article 15. Access to Genetic Resources 
1. Recognizing the sovereign rights of States over their natural resources, the authority to 
determine access to genetic resources rests with the national governments and is subject 
to national legislation. 
2. Each Contracting Party shall endeavour to create conditions to facilitate access to 
genetic resources for environmentally sound uses by other Contracting Parties and not 
to impose restrictions that run counter to the objectives of this Convention. 
3. For the purpose of this Convention, the genetic resources being provided by a 
Contracting Party, as referred to in this Article and Articles 16 and 19, are only those 
that are provided by Contracting Parties that are countries of origin of such resources or 
by the Parties that have acquired the genetic resources in accordance with this 
Convention. 
4. Access, where granted, shall be on mutually agreed terms and subject to the provisions 
of this Article. 
5. Access to genetic resources shall be subject to prior informed consent of the Contracting 
Party providing such resources, unless otherwise determined by that Party. 
6. Each Contracting Party shall endeavour to develop and carry out scientific research 
based on genetic resources provided by other Contracting Parties with the full 
participation of, and where possible in, such Contracting Parties. 
7. Each Contracting Party shall take legislative, administrative or policy measures, as 
appropriate, and in accordance with Articles 16 and 19 and, where necessary, through 
the financial mechanism established by Articles 20 and 21 with the aim of sharing in a 
fair and equitable way the results of research and development and the benefits arising 
from the commercial and other utilization of genetic resources with the Contracting 
Party providing such resources. Such sharing shall be upon mutually agreed terms. 
Article 16. Access to and Transfer of Technology 
1. Each Contracting Party, recognizing that technology includes biotechnology, and that 
both access to and transfer of technology among Contracting Parties are essential 
elements for the attainment of the objectives of this Convention, undertakes subject to 
the provisions of this Article to provide and/or facilitate access for and transfer to other 
Contracting Parties of technologies that are relevant to the conservation and sustainable 
use of biological diversity or make use of genetic resources and do not cause significant 
damage to the environment. 
2. Access to and transfer of technology referred to in paragraph 1 above to developing 
countries shall be provided and/or facilitated under fair and most favourable terms, 
including on concessional and preferential terms where mutually agreed, and, where 
necessary, in accordance with the financial mechanism established by Articles 20 and 
21. In the case of technology subject to patents and other intellectual property rights, 
such access and transfer shall be provided on terms which recognize and are consistent 
with the adequate and effective protection of intellectual property rights. The 
application of this paragraph shall be consistent with paragraphs 3, 4 and 5 below. 
3. Each Contracting Party shall take legislative, administrative or policy measures, as 
appropriate, with the aim that Contracting Parties, in particular those that are 
developing countries, which provide genetic resources are provided access to and 
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transfer of technology which makes use of those resources, on mutually agreed terms, 
including technology protected by patents and other intellectual property rights, where 
necessary, through the provisions of Articles 20 and 21 and in accordance with 
international law and consistent with paragraphs 4 and 5 below. 
4. Each Contracting Party shall take legislative, administrative or policy measures, as 
appropriate, with the aim that the private sector facilitates access to, joint development 
and transfer of technology referred to in paragraph 1 above for the benefit of both 
governmental institutions and the private sector of developing countries and in this 
regard shall abide by the obligations included in paragraphs 1, 2 and 3 above. 
5. The Contracting Parties, recognizing that patents and other intellectual property rights 
may have an influence on the implementation of this Convention, shall cooperate in this 
regard subject to national legislation and international law in order to ensure that such 
rights are supportive of and do not run counter to its objectives. 
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